Nonalkoholisk fedtlever-sygdom ved overvægt og metabolisk syndrom

Camilla Dalby Hansen; Katrine Prier Lindvig; Henning Grønbæk; Lise Lotte Gluud; Maja Thiele; Aleksander Krag

Nonalkoholisk fedtlever-sygdom ved overvægt og metabolisk syndrom

Camilla Dalby Hansen, Katrine Prier Lindvig, Henning Grønbæk, Lise Lotte Gluud, Maja Thiele, Aleksander Krag

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

1 Citationer (Scopus)

24 Downloads (Pure)

Abstract

Non-alcoholic fatty liver disease (NAFLD) is the most frequent liver disease in the world, affecting 25% of the population. Around 6% of people with NAFLD will be at risk of developing advanced fibrosis, but symptoms often first occur very late from a decompensated cirrhosis. We need better referral pathways to identify and treat patients with advanced fibrosis. Non-invasive tests such as FIB-4 and NFS can be used in primary care to identify patients who will benefit from a referral to secondary care.

Bidragets oversatte titel	Management of non-alcoholic fatty liver disease
Originalsprog	Dansk
Artikelnummer	V04220239
Tidsskrift	Ugeskrift for Laeger
Vol/bind	184
Udgave nummer	42
Antal sider	8
ISSN	0041-5782
Status	Udgivet - 2022

Emneord

Humans
Non-alcoholic Fatty Liver Disease/diagnosis
Liver Cirrhosis/complications
Biopsy
Fibrosis
Referral and Consultation
Liver/pathology

Adgang til dokumentet

FulltextForlagets udgivne version, 405 KBLicens: CC BY-NC-ND

https://content.ugeskriftet.dk/sites/default/files/scientific_article_files/2022-10/v04220239_web.pdfLicens: CC BY-NC-ND

Biblioteksadgang?

Tjek tilgængelighed hos det Kgl. Bibliotek

Citationsformater

@article{a5576cb599cc4859bd4bd293adc705ca,

title = "Nonalkoholisk fedtlever-sygdom ved overv{\ae}gt og metabolisk syndrom",

abstract = "Non-alcoholic fatty liver disease (NAFLD) is the most frequent liver disease in the world, affecting 25% of the population. Around 6% of people with NAFLD will be at risk of developing advanced fibrosis, but symptoms often first occur very late from a decompensated cirrhosis. We need better referral pathways to identify and treat patients with advanced fibrosis. Non-invasive tests such as FIB-4 and NFS can be used in primary care to identify patients who will benefit from a referral to secondary care.",

keywords = "Humans, Non-alcoholic Fatty Liver Disease/diagnosis, Liver Cirrhosis/complications, Biopsy, Fibrosis, Referral and Consultation, Liver/pathology",

author = "Hansen, {Camilla Dalby} and Lindvig, {Katrine Prier} and Henning Gr{\o}nb{\ae}k and Gluud, {Lise Lotte} and Maja Thiele and Aleksander Krag",

year = "2022",

language = "Dansk",

volume = "184",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "42",

}

TY - JOUR

T1 - Nonalkoholisk fedtlever-sygdom ved overvægt og metabolisk syndrom

AU - Hansen, Camilla Dalby

AU - Lindvig, Katrine Prier

AU - Grønbæk, Henning

AU - Gluud, Lise Lotte

AU - Thiele, Maja

AU - Krag, Aleksander

PY - 2022

Y1 - 2022

N2 - Non-alcoholic fatty liver disease (NAFLD) is the most frequent liver disease in the world, affecting 25% of the population. Around 6% of people with NAFLD will be at risk of developing advanced fibrosis, but symptoms often first occur very late from a decompensated cirrhosis. We need better referral pathways to identify and treat patients with advanced fibrosis. Non-invasive tests such as FIB-4 and NFS can be used in primary care to identify patients who will benefit from a referral to secondary care.

AB - Non-alcoholic fatty liver disease (NAFLD) is the most frequent liver disease in the world, affecting 25% of the population. Around 6% of people with NAFLD will be at risk of developing advanced fibrosis, but symptoms often first occur very late from a decompensated cirrhosis. We need better referral pathways to identify and treat patients with advanced fibrosis. Non-invasive tests such as FIB-4 and NFS can be used in primary care to identify patients who will benefit from a referral to secondary care.

KW - Humans

KW - Non-alcoholic Fatty Liver Disease/diagnosis

KW - Liver Cirrhosis/complications

KW - Biopsy

KW - Fibrosis

KW - Referral and Consultation

KW - Liver/pathology

M3 - Tidsskriftartikel

C2 - 36305262

SN - 0041-5782

VL - 184

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 42

M1 - V04220239

ER -